Skip to main content
. 2022 Jul 8;14(14):3340. doi: 10.3390/cancers14143340

Figure 5.

Figure 5

Toyocamycin is a potent and specific inhibitor of CDK9. Enzymatic assays were performed with toyocamycin at different concentrations against (A) CDK9/CyclinT1, (B) CDK7/Cyclin H/MAT1, (C) CDK2/Cyclin 2A, (D) CDK4/Cyclin D3, and (E) CDK6/Cyclin D3. Concentration producing 50% enzymatic inhibition (IC50) was calculated for toyocamycin and other inhibitors listed in the graphs.